Westendorp Willeke F, Vermeij Jan-Dirk, Smith Craig J, Kishore Amit K, Hodsoll John, Kalra Lalit, Meisel Andreas, Chamorro Angel, Chang Jason J, Rezaei Yousef, Amiri-Nikpour Mohammad R, DeFalco Fabrizio A, Switzer Jeffrey A, Blacker David J, Dijkgraaf Marcel Gw, Nederkoorn Paul J, van de Beek Diederik
Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Department of Neurology, Sint Franciscusziekenhuis, Heusden-Zolder, Belgium.
Eur Stroke J. 2021 Dec;6(4):385-394. doi: 10.1177/23969873211056445. Epub 2021 Nov 3.
Infection after stroke is associated with unfavorable outcome. Randomized controlled studies did not show benefit of preventive antibiotics in stroke but lacked power for subgroup analyses. Aim of this study is to assess whether preventive antibiotic therapy after stroke improves functional outcome for specific patient groups in an individual patient data meta-analysis.
We searched MEDLINE (1946-7 May 2021), Embase (1947-7 May 2021), CENTRAL (17th September 2021), trial registries, cross-checked references and contacted researchers for randomized controlled trials of preventive antibiotic therapy versus placebo or standard care in ischemic or hemorrhagic stroke patients. Meta-analysis was performed by a one-step and two-step approach. Primary outcome was functional outcome adjusted for age and stroke severity. Secondary outcomes were infections and mortality.
4197 patients from nine trials were included. Preventive antibiotic therapy was not associated with a shift in functional outcome (mRS) at 3 months (OR1.13, 95%CI 0.98-1.31) or unfavorable functional outcome (mRS 3-6) (OR0.85, 95%CI 0.60-1.19). Preventive antibiotics did not improve functional outcome in pre-defined subgroups (age, stroke severity, timing and type of antibiotic therapy, pneumonia prediction scores, dysphagia, type of stroke, and type of trial). Preventive antibiotics reduced infections (276/2066 (13.4%) in the preventive antibiotic group vs. 417/2059 (20.3%) in the control group, OR 0.60, 95% CI 0.51-0.71, < 0.001), but not pneumonia (191/2066 (9.2%) in the preventive antibiotic group vs. 205/2061 (9.9%) in the control group (OR 0.92 (0.75-1.14), = 0.450).
Preventive antibiotic therapy did not benefit any subgroup of patients with acute stroke and currently cannot be recommended.
中风后感染与不良预后相关。随机对照研究未显示预防性使用抗生素对中风有益,但缺乏进行亚组分析的效力。本研究的目的是在一项个体患者数据荟萃分析中评估中风后预防性抗生素治疗是否能改善特定患者群体的功能结局。
我们检索了MEDLINE(1946年至2021年5月7日)、Embase(1947年至2021年5月7日)、CENTRAL(2021年9月17日)、试验注册库,交叉核对参考文献,并联系研究人员获取关于预防性抗生素治疗与安慰剂或标准治疗对比的缺血性或出血性中风患者随机对照试验。荟萃分析采用一步法和两步法进行。主要结局是根据年龄和中风严重程度调整后的功能结局。次要结局是感染和死亡率。
纳入了来自9项试验的4197例患者。预防性抗生素治疗与3个月时功能结局(改良Rankin量表[mRS])的变化无关(比值比[OR]1.13,95%置信区间[CI]0.98 - 1.31),也与不良功能结局(mRS 3 - 6)无关(OR0.85,95%CI 0.60 - 1.19)。预防性抗生素在预定义亚组(年龄、中风严重程度、抗生素治疗时机和类型、肺炎预测评分、吞咽困难、中风类型和试验类型)中未改善功能结局。预防性抗生素减少了感染(预防性抗生素组276/2066例[13.4%],对照组417/2059例[20.3%],OR 0.60,95%CI 0.51 - 0.71,P < 0.001),但未减少肺炎(预防性抗生素组191/2066例[9.2%],对照组205/2061例[9.9%],OR 0.92[0.75 - 1.14],P = 0.450)。
预防性抗生素治疗对急性中风患者的任何亚组均无益处,目前不推荐使用。